Sei Investments Co. Has $2.38 Million Stock Holdings in AxoGen, Inc. $AXGN

Sei Investments Co. increased its position in shares of AxoGen, Inc. (NASDAQ:AXGN) by 38.3% during the 1st quarter, Holdings Channel reports. The fund owned 71,808 shares of the medical equipment provider’s stock after buying an additional 19,886 shares during the quarter. Sei Investments Co.’s holdings in AxoGen were worth $2,379,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of AXGN. MCF Advisors LLC bought a new stake in AxoGen in the fourth quarter valued at approximately $30,000. Aquatic Capital Management LLC boosted its position in shares of AxoGen by 287.8% during the third quarter. Aquatic Capital Management LLC now owns 1,710 shares of the medical equipment provider’s stock worth $31,000 after purchasing an additional 1,269 shares in the last quarter. Arax Advisory Partners boosted its position in shares of AxoGen by 362.4% during the fourth quarter. Arax Advisory Partners now owns 1,045 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 819 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of AxoGen in the 4th quarter valued at $36,000. Finally, Kestra Advisory Services LLC bought a new stake in shares of AxoGen in the 4th quarter valued at $39,000. Institutional investors and hedge funds own 80.29% of the company’s stock.

AxoGen Trading Up 4.7%

AXGN opened at $46.43 on Friday. The stock has a market capitalization of $2.50 billion, a P/E ratio of -68.28 and a beta of 1.11. AxoGen, Inc. has a 12 month low of $13.64 and a 12 month high of $46.95. The firm’s fifty day simple moving average is $42.64 and its 200 day simple moving average is $37.87. The company has a current ratio of 6.60, a quick ratio of 5.04 and a debt-to-equity ratio of 0.07.

AxoGen (NASDAQ:AXGN) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.12 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.12. The firm had revenue of $69.73 million during the quarter, compared to analyst estimates of $67.10 million. AxoGen had a negative net margin of 13.36% and a negative return on equity of 8.90%. As a group, research analysts anticipate that AxoGen, Inc. will post -0.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on AXGN shares. Wells Fargo & Company raised their price objective on AxoGen from $40.00 to $48.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 29th. Jefferies Financial Group reissued a “buy” rating and issued a $55.00 target price on shares of AxoGen in a research note on Wednesday, July 29th. Weiss Ratings restated a “sell (d-)” rating on shares of AxoGen in a report on Friday, May 29th. Raymond James Financial reaffirmed an “outperform” rating and set a $48.00 price target on shares of AxoGen in a research report on Wednesday, April 29th. Finally, Zacks Research upgraded AxoGen from a “strong sell” rating to a “hold” rating in a report on Friday, May 29th. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $51.00.

AxoGen Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.